Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 2/20 | 0.37 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815397 | 0.84 | LMNA (0.49) | HRH3ALDH1A1PBRM1CHKAHTR6 | |
| SCHEMBL4814699 | 0.83 | HRH3 (0.47) | HRH3PBRM1SIGMAR1CHKAIL4I1 | |
| SCHEMBL4814489 | 0.81 | HRH3 (0.56) | HRH3ALDH1A1KDM4EPBRM1ACHE | |
| SCHEMBL4894879 | 0.80 | ALDH1A1 (0.49) | HRH3ALDH1A1KDM4EPBRM1IL4I1 | |
| SCHEMBL4814854 | 0.80 | CRBN (0.50) | HRH3PBRM1SIGMAR1IL4I1HTR6 | |
| SCHEMBL4818862 | 0.80 | HRH3 (0.44) | HRH3ALDH1A1PBRM1CHKA | |
| SCHEMBL4817712 | 0.80 | HRH3 (0.53) | HRH3 | |
| SCHEMBL4817999 | 0.78 | HRH3 (0.47) | HRH3MAOBALDH1A1DRD2SIGMAR1 | |
| SCHEMBL4820190 | 0.77 | KDM4E (0.48) | HRH3ALDH1A1KDM4EPBRM1 | |
| SCHEMBL4818654 | 0.76 | HRH3 (0.40) | HRH3MAOBALDH1A1KDM4EPBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | HRH3 2235/4885MAOB 1261/4885ALDH1A1 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.